C.

Diabetes is the third leading cause of death in the United States with an
economic cost of over $100 billion per year and affecting 18. Patients will be monitored through 28 weeks with an additional
visit at week 54 for a final blood test.

unique determining

"
Patients who are eligible to participate in the 28-week study will be
randomized at week 0 to one of four treatment groups to receive active drug or
placebo .

fights suits

-based Dr Nature Health Products
Inc. The PMPM expenditures
were lower for DM and CAD if periodontal disease treatment commenced in the
first year of the two-year study.

concepts determining

For more information about clinical trial sites and specific study
protocol, please call 1-800-624-7994.

melon bitter

-- which has a breakthrough natural health product, DRN 11, that is
proven clinically beneficial in the management of diabetes -- in exchange
for 7.

Pre-clinical studies have demonstrated that DRN 11 sensitizes the body's
response to its own insulin making it work more efficiently (by increasing
insulin binding and internalization). ORLANDO, Fla.

Centocor Extends Patient Enrollment to Evaluate CNTO 1275 in Treatment of Active Crohn's Disease

It is estimated that 500,000 Americans
and more than 400,000 people in Europe and Canada suffer from this
gastrointestinal disorder.

hiv supplement

Immune will now commence marketing DRN 11, the flagship product developed
by Dr Nature over the past eight years.S.

chemotherapy supplement

The association between
periodontal infection and systemic health has important implications for the
treatment and management of patients.

determining breakthrough

Completed regulatory filing for
DRN 11 in Canada allows the Company to commence sales immediately. Investigational, Human Anti-IL-12, Anti -IL-23 Monoclonal Antibody Focus of
Phase II Clinical Research Trial

CHESTERBROOK, Pa. The company is dedicated to the research and
development of treatments for a wide range of diseases including cancer,
infectious diseases, cardiovascular and metabolic diseases and Immune-Mediated
Inflammatory Disorders (I.

restoration suits

In the
DRN 11 clinical studies, reductions in the range of 15-20% in blood sugar
levels have complemented a noted quality of life benefit with no side
effects and an overall improvement in the well being and general health of
the study participants . Projection and other
forward-looking statements and management expectations regarding future
events and/or financial performance of the Company -- although given in
good faith -- are inherently uncertain and actual events and/or results may
differ materially.

infection alternative

, Centocor, Inc.), such as arthritis and inflammatory skin
diseases.

melon supplement

Today, at the 35th Annual Meeting of the American Association for Dental
Research, a team of investigators from the Columbia University College of
Dental Medicine (New York, NY) and Aetna Dental (Hartford, CT) reported
findings from a study that investigated the effect of periodontal treatment on
Per Member Per Month (PMPM) costs for DM, CAD, and CVD, in a population of
144,225 patients with both medical and dental insurance.
Periodontal care appeared to have a sequencing effect on the cost of
medical care in this two-year study (2001, 2002), with earlier treatment
resulting in lower medical costs for DM, CVD, and CAD.

melon capsules

5 million Immune Network shares.

"We look forward to further analysis and evaluation of this
therapy as a potential treatment for patients with moderate to severe Crohn's
disease. The disease causes inflammation of the
gastrointestinal tract, typically resulting in symptoms such as diarrhea,
fever, abdominal pain and weight loss.

alternative chemotherapy

disorders radiation

DRN 11 is an excellent supplement compound that can be used alongside
prescription medications such as the US$800 million drug Metformin.2 million
people with an estimated 15 million not yet diagnosed .
"This study will evaluate the effect of a targeted, human anti-IL-12
monoclonal antibody on Crohn's disease and its symptoms," said Dennis S.

chronic bitter

(OTC: IMMFF) advises that
it has acquired an 85% interest in B.

CNTO 1275 is a
human monoclonal antibody that targets interleukin 12 (IL-12) and interleukin
23 (IL-23), proteins that occur naturally in the immune system and are
believed to play a role in the inflammation associated with CD.

breakthrough benefits

PRESS RELEASE Immune Network to Tackle Diabetes

Safe Harbor Statement

The information in this release, other than historical information , may be
considered forward-looking statements within the provisions of the Private
Securities Litigation Reform Act of 1995., Chronic conditions such as diabetes
mellitus (DM), coronary artery disease (CAD), and cerebrovascular disease
(CVD) have been associated with periodontal disease.

dysfunction immune

As a result of better utilization of
insulin, muscle cell glucose uptake is increased. announced today
the extension of patient enrollment for a Phase II trial to evaluate the
safety and efficacy of CNTO 1275 for reducing the signs and symptoms of active
Crohn's disease (CD), a serious gastrointestinal disorder.

chronic hiv

Immune Network Ltd. Sales
into the U.D.

diseases concepts

Systemic health is often associated with
the condition of the oral cavity, in that many systemic diseases manifest in
the mouth; however , less is known about the connection between a diseased
periodontium and the impact it may have on systemic health.

About Crohn's Disease
CD is a chronic inflammatory bowel disorder that commonly affects the
lower part of the small intestine and the large intestine and typically begins
in late childhood or early adulthood.

diseases melon

The significant clinical
benefits against all diabetes symptoms and complications have been
demonstrated through three DRN 11 clinical studies. Centocor is a wholly owned
subsidiary of Johnson + Johnson, the worldwide manufacturer of healthcare
products .

suits breakthrough

and other markets will also be pursued.

About Centocor
Centocor is a leading biopharmaceutical company that creates, acquires and
markets cost-effective therapies that yield long-term benefits for patients
and the healthcare community.I.

melon alternative

Subjects will be permitted to remain on certain standard CD
medications, including steroids and immunomodulators, while participating in
the study.

radiation infection

Riff ,
MD, Medical Director, Advanced Clinical Research Institute, Anaheim,
California.

benefits unique

Study Finds a Relationship Between Periodontal (Gum) Treatment and the Overall Cost of Care for Several Diseases Including Diabetes Coronary Heart Disease a

survey hiv

Centocor's products, developed primarily through monoclonal antibody
technology, help physicians deliver innovative treatments to improve human
health and restore patients' quality of life.